Top Reasons to Read This Comparative Effectiveness Research Report
Provide sufficient support to comparative effectiveness efforts with dedicated, well-resourced teams: From a market access perspective, dedicated groups are the best way to ensure that a product is ready for launch. These comparative effectiveness teams can leverage both prospective studies prior to launch and retrospective, post-launch studies, thereby ensuring a continued portfolio of recent and relevant comparative effectiveness data to present to payers. This report discusses managing cross-functional communication for comparative effectiveness activities, as well as ensuring proper resources for CER.
Ensure that those responsible for delivering CER data to payers are able to speak effectively on the whole picture (medical and financial data): Once data has been successfully generated, managed markets groups face the challenge of making sure that CER is useful to the payer and advantageous to the product in question. This process involved the efforts of managed markets account managers, MSLs, and/or HOLs so that they are prepared to effectively deliver a convincing value proposition. Comparative Effectiveness Research discusses how much time companies spend communicating with payers and the factors that drive payer concerns.
Work closely with comparative effectiveness vendors to maximize retrospective studies: The scale of comparative effectiveness research being requested from some payers can present challenges for small and large companies alike. Specialty, boutique health economics vendors can provide significant value to companies while still returning a high-quality product. Use this study for insight on how vendors can be best utilized during the CER process.
Key Questions That This Study Answers about Comparative Effectiveness Research
- Which groups are involved in comparative effectiveness research activities, and how can my company improve cross-functional communication for CER?
- How can my company ensure sufficient resources for CER?
- When is it best to begin conducting CER studies, and how much do other companies spend per study overall and per month?
- Which factors, including therapeutic area and market position, most influence CER decision making?
- How can health outcomes liaisons support managed markets account managers in presenting this information?
- When should companies begin HTA discussions and how much time should be spent on these assessments?
- How has the decision-making process regarding product value changed in focus, and how does CER fit into that model?
- In what ways can companies develop systems and implement CER that engages all stakeholders?
- How are payers using CER data in their decision-making processes?
|Publication Date||July 2015|
|Charts / Graphics||40 +|